Clinical Trials
2 trialsNCT01605396 2019-03-25
MK-8669-064
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT01234857 2017-05-31
A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3)
Merck Sharp & Dohme LLC
Phase 2 Completed